Form 4: Veracyte Executive John Leite Sells 1,277 Shares Under 10b5-1 Plan
SEC Form 4 Filing
John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., sold 1,277 shares of common stock at $25 per share on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 16, 2024, John Leite, the Chief Commercial Officer-CLIA of Veracyte, Inc., sold 1,277 shares of the company's common stock.
- The sale was executed at a price of $25 per share.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 1, 2024.
- Following the transaction, Leite directly owns 82,968 shares of Veracyte common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by company executives are a normal part of corporate activity. The use of a 10b5-1 plan indicates the executive is selling shares according to a pre-arranged schedule to avoid any concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Date the reporting person adopted the Rule 10b5-1 plan |
| July 16, 2024 | Date of the transaction (stock sale) |
| July 18, 2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.